Pain Therapeutics Tradong Over 45% Lower After FDA Rejection

Pfizer PFE and Pain Therapeutics, Inc. PTIE announced that a Complete Response Letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY Extended-Release Capsules CII. Read more here.